{平台标识} {固定描述} Maxim, a financial research firm, recently upgraded its rating on Gilead Sciences (GILD) to ‘Buy’. The upgrade may reflect heightened analyst confidence in the company’s product pipeline and strategic direction. Gilead, best known for its HIV and oncology treatments, continues to operate in a competitive biopharmaceutical landscape.
Maxim Upgrades Gilead Sciences to 'Buy': What This Could Mean for Investors - {财报副标题}
News Analysis
© 2026 Market Analysis. All data is for informational purposes only.